So if the results were great on the 12 patients, why not do an interim analysis on the 150 phase 3 patients? The numbers should be fantastic on the larger sample and provide the statistical basis for a EUA.
The reason given of having to stop enrollment during that analysis is not true.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.